Lipocine receives CRL By: MarketMinute.com Stock News June 29, 2016 at 16:54 PM EDT The Food and Drug Administration issued a Complete Response Letter to Lipocine Inc. (Nasdaq: LPCN) for LPCN 1021. Shares of the specially pharmaceutical plummeted $3.17 to close at $3.10. Related Stocks: Lipocine Inc